Paroxetine HCl Clinical Trials

Size	Price	Qty
10mg	USD 147
50mg	USD 370

Clinical Trials

Numerous clinical trials spanning Early Phase 1 through Phase 4 evaluate Paroxetine HCl across various neuropsychiatric and systemic conditions, including major depressive disorder, anxiety, insomnia, post-traumatic stress disorder, and vasomotor symptoms. Sponsored by academic institutions, medical research foundations, and pharmaceutical entities, these studies feature recruitment statuses ranging from completed and actively recruiting to withdrawn or not yet recruiting. Research encompasses drug-interaction studies, comparative symptom management, and novel applications such as G-protein coupled receptor kinase 2 inhibition in rheumatoid arthritis.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07070232	RECRUITING	Advanced Solid Tumor	BioNTech SE	2025-08-12	PHASE1; PHASE2
NCT07318181	RECRUITING	Post Traumatic Stress Disorder; Post Traumatic Stress Disorder PTSD; Post-Traumatic Stress Disorder, PTSD	University of Luxembourg	2026-01-01
NCT07715669	RECRUITING	Preeclampsia; Endothelial Function	Anna Stanhewicz, PhD	2026-08-30	EARLY_PHASE1
NCT07025590	RECRUITING	Cardiovascular Diseases (CVD); Depression Anxiety Disorder	Guangdong Provincial People's Hospital	2025-04-22
NCT06796946	NOT_YET_RECRUITING	Deprescription; Antidepressants	University of Huelva	2026-06	EARLY_PHASE1
NCT06799169	ACTIVE_NOT_RECRUITING	Tinnitus	University of California, Irvine	2025-06-01	PHASE4
NCT04961190	ACTIVE_NOT_RECRUITING	Posttraumatic Stress Disorder	University of Pennsylvania	2022-05-25	PHASE4
NCT07669571	NOT_YET_RECRUITING	Healthy Adult Participants	NeuShen Therapeutics	2026-06	PHASE1
NCT07057011	NOT_YET_RECRUITING	Premature Ejaculation	South Valley University	2025-07-01
NCT05725837	COMPLETED	Septic Shock; Sepsis	Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude	2023-06-10	PHASE2
NCT04207723	COMPLETED	Premature Ejaculation	Boston Medical Group	2020-07-15
NCT06763484	COMPLETED	Menopause Syndrome; Menopause Surgical; Hot Flashes	Universidad Nacional Autonoma de Honduras	2025-01-30	PHASE2
NCT06231745	COMPLETED	Rheumatoid Arthritis	Mostafa Bahaa	2024-01-31	PHASE3
NCT06203275	UNKNOWN	Diabetes Mellitus, Type 2	aya ramadan ashmawy sarhan	2024-01	PHASE3
NCT04757571	WITHDRAWN	Rheumatoid Arthritis	Sadat City University	2021-02-01	PHASE1; PHASE2
NCT06232109	COMPLETED	Drug Drug Interaction	Asceneuron S.A.	2024-02-22	PHASE1
NCT05175430	COMPLETED	Healthy	University Hospital, Basel, Switzerland	2022-10-24	PHASE1
NCT06065735	COMPLETED	Anxiety Disorders	GlaxoSmithKline	2023-10-02	PHASE1
NCT04404439	COMPLETED	Tinnitus, Subjective; Tinnitus	University of California, Irvine	2019-09-26	PHASE4
NCT05637671	UNKNOWN	Vasomotor Symptoms	Cairo University	2022-02-10	PHASE3
NCT05992428	COMPLETED	Healthy	Dong-A ST Co., Ltd.	2023-08-22	PHASE1
NCT06025474	UNKNOWN	Burning Mouth Syndrome	Federico II University	2023-01-01	PHASE3
NCT05470465	COMPLETED	Hypercapnia; Ventilatory Depression	Food and Drug Administration (FDA)	2022-09-01	PHASE1
NCT04218981	COMPLETED	Common Mental Disorder	Central South University	2020-01-15
NCT05588102	COMPLETED	Geriatric Depression; Cognitive Impairment	Capital Medical University	2021-05-18
NCT05730062	Not yet recruiting	Opioid Induced Respiratory Depression\|Depressive Disorder\|Anxiety Disorders	Leiden University Medical Center	2023-03-15	Phase 1
NCT03779789	COMPLETED	Major Depressive Disorder	Azienda Ospedaliera Universitaria Integrata Verona	2019-02-01	PHASE4
NCT03894085	COMPLETED	Anxiety Disorder; Obsessive-Compulsive Disorder	Central South University	2019-05-30
NCT05637671	Recruiting	Vasomotor Symptoms	Cairo University	2022-02-10	Phase 3
NCT05188833	UNKNOWN	Obsessive-Compulsive Disorder; EEG With Periodic Abnormalities	Istanbul Medipol University Hospital	2020-05-17
NCT04650542	COMPLETED	Drug-drug Interaction	HUYABIO International, LLC.	2021-02-21	PHASE1
NCT04888728	COMPLETED	Idiopathic Pulmonary Fibrosis	Daewoong Pharmaceutical Co. LTD.	2021-06-30	PHASE1
NCT04981704	COMPLETED	Healthy	Spectrum Pharmaceuticals, Inc	2021-04-08	PHASE1
NCT04310579	COMPLETED	Hypercapnia; Ventilatory Depression	Food and Drug Administration (FDA)	2020-06-15	PHASE1
NCT04311463	COMPLETED	Anxiety Disorders	GlaxoSmithKline	2020-12-09	PHASE1
NCT03274752	COMPLETED	Cardiac Remodeling; Myocardial Infarction	Insel Gruppe AG, University Hospital Bern	2017-10-26	PHASE2
NCT03879746	UNKNOWN	Premature Ejaculation	Assiut University	2019-04	PHASE3
NCT03277339	COMPLETED	Generalized Anxious Disorders	Centre Hospitalier Henri Laborit	2017-01-19	PHASE4
NCT02655354	COMPLETED	Posttraumatic Stress Disorder; Depression; Alcohol-Related Disorders; Suicidal Ideation; Substance-Related Disorders; Mild Cognitive Impairment; Quality of Life; Pain; Wounds and Injury; Brain Injuries; Chronic Disease	University of Washington	2015-10
NCT04188028	COMPLETED	Healthy	Jules Desmeules	2019-01-01
NCT03054220	COMPLETED	Healthy	Jules Desmeules	2016-07
NCT03329573	COMPLETED	Anxiety Disorders	GlaxoSmithKline	2018-05-30	PHASE1
NCT03504475	COMPLETED	Major Depressive Disorder; Obsessive-Compulsive Disorder; Panic Disorder; Social Anxiety Disorder; Generalized Anxiety Disorder	Beijing Tongren Hospital	2018-03-29	PHASE1
NCT03312777	COMPLETED	Pain	Syntrix Biosystems, Inc.	2017-10-31	PHASE1
NCT02022709	COMPLETED	Obsessive-Compulsive Disorder; Anxiety Disorders; Mental Disorders	Shanghai Mental Health Center	2014-01	PHASE4
NCT03149419	COMPLETED	Postmenopausal Flushing; Cardiovascular Risk Factor; Endothelial Dysfunction	Rio de Janeiro State University	2016-03-01	PHASE4
NCT02374567	TERMINATED	Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders	Hannover Medical School	2015-01	PHASE3
NCT02932904	COMPLETED	Healthy Volunteers	Takeda	2016-11-21	PHASE4
NCT01360866	COMPLETED	Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders	Otsuka Pharmaceutical Development & Commercialization, Inc.	2011-10	PHASE3
NCT01458626	COMPLETED	Major Depression	Capital Medical University	2012-11-14	PHASE4
NCT02681198	COMPLETED	Healthy	USWM, LLC (dba US WorldMeds)	2016-01	PHASE1
NCT01354314	COMPLETED	HIV Associated Neurocognitive Disorder	Johns Hopkins University	2010-11	PHASE1; PHASE2
NCT02279966	COMPLETED	Major Depressive Disorder	H. Lundbeck A/S	2014-10	PHASE3
NCT02273154	UNKNOWN	Major Depression Disorder	Si Tianmei	2014-08	PHASE4
NCT01987960	TERMINATED	Post-traumatic Stress Disorder; PTSD	H. Lundbeck A/S	2013-12	PHASE3
NCT01608295	COMPLETED	Major Depressive Disorder	University of California, Los Angeles	2012-07	PHASE4
NCT00338962	COMPLETED	Alcoholism; Depression; PTSD	Yale University	2001-10	PHASE3
NCT01681849	COMPLETED	PTSD	Emory University	2009-07	PHASE4
NCT00926835	TERMINATED	Major Depressive Disorder	Ministry of Health & Welfare, Korea	2009-05	PHASE4
NCT01748955	COMPLETED	Depression; Suicidal Ideation	New York State Psychiatric Institute	2010-06	PHASE4
NCT02237937	UNKNOWN	Major Depression	HolsboerMaschmeyer NeuroChemie GmbH	2011-09	PHASE4
NCT01289756	COMPLETED	Anovulation; Disorder Due Cytochrome P450 CYP2D6 Variant; Cytochrome P450 CYP3A Enzyme Deficiency	Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)	2009-12	PHASE1
NCT01764867	UNKNOWN	Major Depressive Disorder	Shanghai Mental Health Center	2012-06	PHASE4
NCT02097147	COMPLETED	Healthy	Forest Laboratories	2014-03	PHASE1
NCT02451475	COMPLETED	Fibromyalgia	Mansoura University	2013-02	PHASE1; PHASE2
NCT01841502	TERMINATED	Hepatitis C Infection; Depression	Radboud University Medical Center	2013-05	PHASE2
NCT01916200	WITHDRAWN	Depressive Disorder	GlaxoSmithKline	2014-01	PHASE4
NCT01896349	UNKNOWN	Treatment Resistant Depression	Hospital de Clinicas de Porto Alegre	2013-04
NCT02174822	COMPLETED	Drug-drug Interaction	Otsuka Pharmaceutical Development & Commercialization, Inc.	2014-01	PHASE1
NCT01318434	COMPLETED	Major Depressive Disorder	Euthymics BioScience, Inc.	2011-02	PHASE2; PHASE3
NCT01416220	WITHDRAWN	Major Depressive Disorder	Nova Scotia Health Authority	2011-09	PHASE4
NCT00400088	TERMINATED	Major Depressive Disorder	Nova Scotia Health Authority	2007-06	PHASE3
NCT02191124	COMPLETED	Major Depressive Disorder	Capital Medical University	2011-06	PHASE4
NCT02852577	COMPLETED	Panic Disorder; Agoraphobia	Universidade Federal do Rio de Janeiro	2000-01	PHASE4
NCT01254305	COMPLETED	Major Depressive Disorder	Forest Laboratories	2011-04	PHASE2
NCT00291148	COMPLETED	Neuropathic Pain; Multiple Sclerosis	University of Manitoba	2006-03	PHASE3
NCT00700999	COMPLETED	Post-traumatic Stress Disorder	US Department of Veterans Affairs	2008-10	PHASE4
NCT00665678	TERMINATED	Posttraumatic Stress Disorder (PTSD)	Foundation for Atlanta Veterans Education and Research, Inc.	2008-04	PHASE4
NCT01386593	COMPLETED	Metabolic Detoxication, Phase I	University Hospital, Basel, Switzerland	2011-05	PHASE1
NCT01361308	COMPLETED	Postmenopausal Symptoms	Noven Therapeutics	2011-05	PHASE3
NCT01101841	COMPLETED	Hot Flashes	Noven Therapeutics	2010-03	PHASE3
NCT01829919	COMPLETED	Postmenopausal Symptoms	Noven Therapeutics	2011-07	PHASE1
NCT00403455	COMPLETED	PTSD	VA Office of Research and Development	2006-10	PHASE3
NCT01318031	COMPLETED	Healthy Volunteers	Pfizer	2011-03	PHASE1
NCT00641173	WITHDRAWN	Post-Traumatic Stress Disorders	US Department of Veterans Affairs	2008-09
NCT00812812	TERMINATED	Depressive Disorder	GlaxoSmithKline	2009-03	PHASE4
NCT00519012	UNKNOWN	Depression	Oizumi Hospital	2007-08	PHASE4
NCT00594269	COMPLETED	Dementia	Sykehuset Innlandet HF	2008-08	PHASE4
NCT00218439	COMPLETED	Tobacco Use Disorder	University of Minnesota	2005-10
NCT01000857	COMPLETED	Depressive Disorder	GlaxoSmithKline	2009-11-05	PHASE1
NCT01130103	COMPLETED	Posttraumatic Stress Disorder	Research Foundation for Mental Hygiene, Inc.	2004-03	PHASE4
NCT00866294	COMPLETED	Depressive Disorder	GlaxoSmithKline	2009-04	PHASE3
NCT00677352	COMPLETED	Panic Disorder	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2008-05	PHASE4
NCT00429169	TERMINATED	Depression	New York State Psychiatric Institute	2004-06	PHASE4
NCT00879099	COMPLETED	Healthy	Santen Oy	2009-04	PHASE1
NCT00184106	COMPLETED	Phobic Disorders	Norwegian University of Science and Technology	2004-10	PHASE4
NCT00736346	UNKNOWN	Panic Disorder; Anxiety Disorder; Mental Disorder	Université du Québec a Montréal	2005-10
NCT01339247	COMPLETED	Depressive Disorder	GlaxoSmithKline	2009-10-20	PHASE1
NCT00086190	COMPLETED	Parkinson Disease; Depression	University of Rochester	2005-06	PHASE3
NCT01316926	COMPLETED	Depressive Disorder	GlaxoSmithKline	2009-09-09	PHASE1
NCT00938184	COMPLETED	Depressive Disorder	GlaxoSmithKline	2009-07-14	PHASE1
NCT00394056	COMPLETED	Tinnitus	GlaxoSmithKline	2006-12	PHASE2
NCT00786188	COMPLETED	Hot Flashes	Noven Therapeutics	2008-11	PHASE2
NCT00658762	TERMINATED	Generalized Anxiety Disorder	Pfizer	2008-05	PHASE3
NCT00658372	TERMINATED	Generalized Anxiety Disorder	Pfizer	2008-05	PHASE3
NCT00658008	TERMINATED	Generalized Anxiety Disorder	Pfizer	2008-04	PHASE3
NCT01024491	COMPLETED	Premature Ejaculation	MorePharma Corporation	2008-08	PHASE3
NCT00629551	COMPLETED	Depressive Disorder, Major	Sanofi	2008-02	PHASE3
NCT00445679	COMPLETED	Depressive Disorder, Major	Wyeth is now a wholly owned subsidiary of Pfizer	2007-07	PHASE3
NCT00836069	TERMINATED	Anxiety Disorders	Cedars-Sinai Medical Center	2008-10	PHASE3
NCT00666757	COMPLETED	Depression	Eli Lilly and Company	2008-05	PHASE4
NCT00470483	COMPLETED	Social Phobia	GlaxoSmithKline	2007-01-22	PHASE1
NCT00062738	COMPLETED	Parkinson Disease; Depression	Rutgers, The State University of New Jersey	2003-06	PHASE2
NCT00557622	TERMINATED	Post-Traumatic Stress Disorder; Stress Disorders, Post-Traumatic	GlaxoSmithKline	2008-01-25	PHASE2
NCT02264184	COMPLETED	Healthy	Boehringer Ingelheim	2008-09	PHASE1
NCT00292370	COMPLETED	Combat Disorders; Stress Disorders, Post-Traumatic	VA Office of Research and Development	2006-01	PHASE4
NCT00749359	COMPLETED	Depressive Disorder	GlaxoSmithKline	2008-07-07	PHASE1
NCT00680602	COMPLETED	Obsessive Compulsive Disorder	University of Sao Paulo	2006-01	PHASE4
NCT00785603	UNKNOWN	Depression; Pain	University of Southern Denmark	2008-08	PHASE4
NCT00560612	COMPLETED	Stress Disorders, Post-Traumatic	Durham VA Medical Center	2006-01	PHASE4
NCT00420641	COMPLETED	Depressive Disorder	GlaxoSmithKline	2006-12-19	PHASE2
NCT00463242	COMPLETED	Major Depressive Disorder	Novartis	2007-03	PHASE3
NCT00074802	COMPLETED	Social Anxiety Disorder	Temple University	2003-12	PHASE3
NCT00246441	COMPLETED	Social Anxiety Disorder; Social Phobia; Alcohol Use Disorder; Alcohol Abuse; Alcohol Dependence	Medical University of South Carolina	2002-03	PHASE4
NCT00374166	COMPLETED	Anxiety Disorders	Sanofi	2006-08	PHASE2
NCT00202449	TERMINATED	Stress Disorders, Post-Traumatic; Sleep Disorders	Seattle Institute for Biomedical and Clinical Research	2004-07
NCT00385307	COMPLETED	Major Depressive Disorder	Sanofi	2006-09	PHASE3
NCT00397722	COMPLETED	Social Phobia	GlaxoSmithKline	2006-11-09	PHASE2
NCT00361491	COMPLETED	Depressive Disorder	Sanofi	2006-08	PHASE2
NCT00672776	COMPLETED	Posttraumatic Stress Disorder (PTSD)	Emory University	2003-05	PHASE4
NCT00261729	COMPLETED	Sleep Disorders; Stress Disorders, Post-Traumatic	US Department of Veterans Affairs	2004-07
NCT00249847	TERMINATED	Hot Flashes	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2005-10
NCT00767754	COMPLETED	Panic Disorder	Samsung Medical Center	2007-01	PHASE4
NCT00332891	COMPLETED	Anxiety Disorders	Sanofi	2006-03	PHASE3
NCT00113295	COMPLETED	Anxiety Disorder	Massachusetts General Hospital	2004-02	PHASE4
NCT00266747	COMPLETED	Anxiety Disorders	Sanofi	2005-12	PHASE3
NCT00648193	COMPLETED	Healthy	Mylan Pharmaceuticals Inc	2006-12	EARLY_PHASE1
NCT00650403	COMPLETED	Healthy	Mylan Pharmaceuticals Inc	2006-12	PHASE1
NCT00318669	COMPLETED	Social Phobia	GlaxoSmithKline	2005-12	PHASE3
NCT00744406	COMPLETED	Depression; Major Depressive Disorder	Centre for Addiction and Mental Health	2003-07	PHASE2
NCT00273039	COMPLETED	Social Anxiety Disorder; Anxiety Disorders	GlaxoSmithKline	2005-08	PHASE2
NCT00413023	COMPLETED	Depressive Disorder, Major	GlaxoSmithKline	2005-06	PHASE2
NCT01367535	COMPLETED	Healthy Adults	Bausch Health Americas, Inc.	2006-03	PHASE1
NCT00901407	COMPLETED	Unipolar Depression	Louisiana State University Health Sciences Center in New Orleans	2003-12
NCT00406432	COMPLETED	Depressive Disorder	GlaxoSmithKline	2006-05-09	PHASE1
NCT00229528	COMPLETED	Coronary Artery Disease	University of Oklahoma	2004-03	PHASE4
NCT00406003	COMPLETED	Depressive Disorder	GlaxoSmithKline	2006-03-24	PHASE1
NCT00195598	COMPLETED	Panic Disorders	Wyeth is now a wholly owned subsidiary of Pfizer	2005-01	PHASE3
NCT00259883	COMPLETED	Mental Disorders	GlaxoSmithKline	2005-06	PHASE4
NCT00264654	COMPLETED	Social Phobia	GlaxoSmithKline	2005-10	PHASE3
NCT00343707	COMPLETED	Depressive Disorder and Anxiety Disorders	GlaxoSmithKline	2004-11	PHASE2
NCT00135525	COMPLETED	Anxiety Disorder; Anxiety Disorders	GlaxoSmithKline	2003-05	PHASE2
NCT00206765	TERMINATED	Major Depressive Disorder With Panic Attacks; Panic Disorder	Beth Israel Medical Center	2003-01	PHASE2
NCT00647881	COMPLETED	Healthy	Mylan Pharmaceuticals Inc	2005-04	PHASE1
NCT00648427	COMPLETED	Healthy	Mylan Pharmaceuticals Inc	2005-04	PHASE1
NCT00067444	COMPLETED	Depressive Disorder, Major; Major Depressive Disorder (MDD)	GlaxoSmithKline	2003-06	PHASE3
NCT00839397	COMPLETED	Post-Traumatic Stress Disorder	GlaxoSmithKline	2002-05	PHASE3
NCT00825019	COMPLETED	Major Depressive Disorders	Sanofi	2003-09	PHASE3
NCT00000368	COMPLETED	Panic Disorder; Agoraphobia	New York State Psychiatric Institute	1999-02	PHASE3
NCT00825058	COMPLETED	Major Depressive Disorders	Sanofi	2003-11	PHASE3
NCT00048607	COMPLETED	Major Depressive Disorder	Merck Sharp & Dohme LLC	2002-07-30	PHASE3
NCT00034983	COMPLETED	Major Depressive Disorder	Merck Sharp & Dohme LLC	2001-10-29	PHASE3
NCT00035009	COMPLETED	Major Depressive Disorder	Merck Sharp & Dohme LLC	2001-09-20	PHASE3
NCT00100464	COMPLETED	Obstructive Sleep Apnea	US Department of Veterans Affairs	2000-11	PHASE4
NCT00048204	COMPLETED	Depressive Disorder, Major	GlaxoSmithKline	2002-11-04	PHASE2
NCT00049972	COMPLETED	Major Depressive Disorder	GlaxoSmithKline	2002-09	PHASE4
NCT00457106	COMPLETED	Major Depression With Panic Attacks; Panic Disorder	Beth Israel Medical Center	2002-06
NCT00044772	COMPLETED	Panic Disorder	Wyeth is now a wholly owned subsidiary of Pfizer	2001-11	PHASE3
NCT00610909	COMPLETED	Irritable Bowel Syndrome	Duke University	2002-01	PHASE4
NCT00610610	COMPLETED	Fibromyalgia Syndrome	Duke University	2002-01	PHASE4
NCT00841698	COMPLETED	Healthy	Teva Pharmaceuticals USA	2002-10	PHASE1
NCT00841659	COMPLETED	Healthy	Teva Pharmaceuticals USA	2002-08	PHASE1
NCT01049347	COMPLETED	Unipolar Depression	Central Institute of Mental Health, Mannheim	1997-10	PHASE3
NCT00119652	COMPLETED	Bipolar Disorder; Bipolar Depression; Depression	AstraZeneca	2005-05	PHASE3
NCT00516113	COMPLETED	Premenstrual Dysphoric Disorder; Premenstrual Syndrome	Karolinska Institutet	2000-10	PHASE4
NCT00136383	COMPLETED	Depressive Symptoms	Duke University	2005-03	PHASE2; PHASE3
NCT00351910	COMPLETED	Major Depressive Disorder	AstraZeneca	2006-05	PHASE3
NCT00196664	COMPLETED	Chronic Hepatitis C	French National Agency for Research on AIDS and Viral Hepatitis	2005-10	PHASE3
NCT00322595	COMPLETED	Generalized Anxiety Disorder	AstraZeneca	2006-05	PHASE3
NCT00178100	COMPLETED	Unipolar Depression	University of Pittsburgh	1999-03	PHASE4
NCT00620581	COMPLETED	Premenstrual Dysphoric Disorder	Hamilton Health Sciences Corporation		PHASE3
NCT01159821	COMPLETED	Healthy	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2010-08	PHASE1
NCT00018759	COMPLETED	Depression; Hypertension	US Department of Veterans Affairs	2001-03	PHASE4
NCT00456560	COMPLETED	Healthy	Avigen	2007-04	PHASE1
NCT00403962	COMPLETED	Social Phobia	GlaxoSmithKline	2004-11	PHASE2
NCT00018733	COMPLETED	Depression	US Department of Veterans Affairs	1996-09
NCT00357045	COMPLETED	Major Depression	Portland VA Medical Center		PHASE4
NCT00489775	COMPLETED	Major Depressive Disorder	Eli Lilly and Company	2004-01	PHASE3
NCT00791713	COMPLETED	Schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2006-03	PHASE1
NCT00191022	COMPLETED	Social Phobia	Eli Lilly and Company	2004-12	PHASE2
NCT00209118	COMPLETED	Hepatitis C; Depression; Interferon-alpha Associated Side Effects	Emory University
NCT00492414	UNKNOWN	Panic Disorder	Inje University		PHASE4
NCT00269334	UNKNOWN	Major Depression	National Health Research Institutes, Taiwan	2005-12	PHASE4
NCT00540098	COMPLETED	Panic Disorder	University of Göttingen	2001-09	PHASE4
NCT00456898	COMPLETED	Depressive Disorder, Major; Diabetic Neuropathies; Fibromyalgia; Vasomotor Symptoms	Wyeth is now a wholly owned subsidiary of Pfizer	2007-01	PHASE1
NCT00330239	COMPLETED	PTSD	Medical University of South Carolina	2003-01	PHASE4
NCT00177567	COMPLETED	Bipolar Disorder	University of Pittsburgh	2001-07	PHASE4
NCT00178035	COMPLETED	Depression	University of Pittsburgh	1999-12	PHASE4
NCT00025740	COMPLETED	Post Traumatic Stress Disorder	National Institute of Mental Health (NIMH)	2001-10	PHASE4
NCT00215163	COMPLETED	Stress Disorders, Post-Traumatic	Duke University	2002-12	PHASE2; PHASE3
NCT00715039	COMPLETED	Anxiety Disorders	Pfizer	2003-10
NCT00178048	COMPLETED	Primary Insomnia; Depression	University of Pittsburgh	1998-09	PHASE4
NCT00121888	COMPLETED	Stress Disorders, Post-Traumatic	Massachusetts General Hospital	2002-12	PHASE1; PHASE2
NCT00368303	COMPLETED	Depressive Disorder, Major; Major Depressive Disorder (MDD)	GlaxoSmithKline	2006-12	PHASE3
NCT00012558	COMPLETED	Bipolar Disorder	National Institute of Mental Health (NIMH)	1998-09
NCT00073203	COMPLETED	Major Depressive Disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.		PHASE2
NCT00225914	COMPLETED	Menopause	Massachusetts General Hospital	2004-09	PHASE4
NCT00031317	COMPLETED	Panic Disorder	National Institute of Mental Health (NIMH)	2002-02	PHASE4
NCT00329147	COMPLETED	Depression	Wyeth is now a wholly owned subsidiary of Pfizer	2006-05	PHASE3

(data from https://clinicaltrials.gov, updated on 2026-09-02)

Check the Paroxetine HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Paroxetine HCl functions as a potent and selective inhibitor of the presynaptic serotonin transporter, binding directly to the carrier protein to block the reuptake of extracellular serotonin into presynaptic terminals. This inhibition elevates active synaptic serotonin concentrations within the central nervous system, enhancing serotonergic signaling to mitigate symptoms in clinical trial conditions such as major depressive disorder, panic disorders, and anxiety disorders.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).